FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W596445770> ?p ?o ?g. }

• W596445770 abstract "Protein engineering is a powerful tool to modify proteins to generate novel and desired properties that could be applied in biotechnological, diagnostics and therapeutic areas. In this thesis, both rational design and library based engineering principles have been exploited to develop affinity proteins with desired traits.One study was focused on the use of site-directed mutagenesis to obtain variants of the staphylococcal protein A-derived 58-residue immunoglobulin binding Z domain with improved affinity for mouse IgG1 Fc. Screening of ca. 170 constructed variants revealed one variant with a single F5I amino acid substitution, denoted ZF5I, with a ten-fold higher affinity. The Fc binding ZF5I variant was further investigated for use in affinity-driven site-specific covalent photoconjugation to mIgG1 monoclonal antibodies. Here, nine candidate positions in the domain were investigated for introduction of a UV-activatable maleimide benzophenone (MBP) group via conjugation to an introduced cysteine residue. The best photo-conjugation results were obtained for a variant in which the MBP was introduced at position 32, denoted ZF5I-Q32C-MBP, which could be conjugated at high yields to all nineteen mouse IgG1s tested. The use of a biotinylated Z-based probe for biotinylation via photoconjugation of a monoclonal anti-interferon gamma antibody resulted in a higher antigen binding activity than if a conventional amine directed biotinylation strategy was used.In a second study, the goal was to develop a new homogeneous immunoassay for quick antigen detection, based on split-protein complementation and pairs of antigen recognizing proteins. In one of the formats investigated, separate fragments of a split-beta-lactamase enzyme reporter were genetically linked to ZF5I-Q32C-MBP units which were individually photo-conjugated to two different mAbs recognizing different epitopes on a human interferon gamma model target analyte. Simultaneous binding of the two mAb-enzyme half probes to the analyte resulted in an analyte concentration-dependent enzyme fragment complementation which could be spectrophotometrically detected using a nitrocefin substrate.Using ribosome display technology, Z-domain based binders to mouse IgG1 were selected from an affibody library. One binder denoted Zmab25 was shown capable of selective binding to mouse IgG in a background of bovine IgG, and could be used for species-selective recovery of monoclonal antibodies from complex samples, resembling hybridoma culture supernatants. Epitope mapping experiments showed that that the binding site on mouse IgG was located in the Fab fragment and was overlapping with that of streptococcal protein G.In a final study, phage display technology was used to select affibodies binding to human interleukin 6 (IL-6), for potential use in rheumatoid arthritis (RA) therapy via blocking of the signaling involving the ternary complex between IL-6, the IL-6 receptor α (IL-6R α) and the gp130 co-receptor. Several affibodies were shown to be capable of blocking the interaction between gp130 and preformed complexes of IL-6 and soluble IL-6R α (IL-6/sIL-6R α) in vitro, corresponding to the so-called trans-signaling interaction. One of these affibody variants denoted ZIL-6_13 showed a KD of approx. 500 pM for IL-6 and was genetically fused to different chain ends of the monoclonal anti-TNF antibody adalimumab to build bi-specific “AffiMab” constructs. One construct, ZIL-6_13-HCAda,in which the affibody was fused to the N-terminus of the adalimumab heavy chain had the most optimal properties in different cell assays and was also evaluated in vivo in an acute serum amyloid A (SAA) mouse RA model, involving a dual challenge of animals with both IL-6 and TNF. Compared to adalimumab that could only reduce SAA levels to 50% at the highest dose, the bi-functional AffiMab reduced SAA levels to below the detection level." @default.
• W596445770 created "2016-06-24" @default.
• W596445770 creator A5026225987 @default.
• W596445770 creator A5060438459 @default.
• W596445770 creator A5080448256 @default.
• W596445770 date "2015-01-01" @default.
• W596445770 modified "2023-09-26" @default.
• W596445770 title "Site-specific photoconjugation of betalactamase split-protein fragments to monoclonal antibodies for homogeneous assay development" @default.
• W596445770 hasPublicationYear "2015" @default.
• W596445770 type Work @default.
• W596445770 sameAs 596445770 @default.
• W596445770 citedByCount "0" @default.
• W596445770 crossrefType "journal-article" @default.
• W596445770 hasAuthorship W596445770A5026225987 @default.
• W596445770 hasAuthorship W596445770A5060438459 @default.
• W596445770 hasAuthorship W596445770A5080448256 @default.
• W596445770 hasConcept C104317684 @default.
• W596445770 hasConcept C123894998 @default.
• W596445770 hasConcept C147483822 @default.
• W596445770 hasConcept C153911025 @default.
• W596445770 hasConcept C159654299 @default.
• W596445770 hasConcept C185592680 @default.
• W596445770 hasConcept C186268636 @default.
• W596445770 hasConcept C203014093 @default.
• W596445770 hasConcept C204628709 @default.
• W596445770 hasConcept C2779281246 @default.
• W596445770 hasConcept C2780420688 @default.
• W596445770 hasConcept C2780676925 @default.
• W596445770 hasConcept C40767141 @default.
• W596445770 hasConcept C542903549 @default.
• W596445770 hasConcept C54355233 @default.
• W596445770 hasConcept C55493867 @default.
• W596445770 hasConcept C86803240 @default.
• W596445770 hasConcept C9086966 @default.
• W596445770 hasConceptScore W596445770C104317684 @default.
• W596445770 hasConceptScore W596445770C123894998 @default.
• W596445770 hasConceptScore W596445770C147483822 @default.
• W596445770 hasConceptScore W596445770C153911025 @default.
• W596445770 hasConceptScore W596445770C159654299 @default.
• W596445770 hasConceptScore W596445770C185592680 @default.
• W596445770 hasConceptScore W596445770C186268636 @default.
• W596445770 hasConceptScore W596445770C203014093 @default.
• W596445770 hasConceptScore W596445770C204628709 @default.
• W596445770 hasConceptScore W596445770C2779281246 @default.
• W596445770 hasConceptScore W596445770C2780420688 @default.
• W596445770 hasConceptScore W596445770C2780676925 @default.
• W596445770 hasConceptScore W596445770C40767141 @default.
• W596445770 hasConceptScore W596445770C542903549 @default.
• W596445770 hasConceptScore W596445770C54355233 @default.
• W596445770 hasConceptScore W596445770C55493867 @default.
• W596445770 hasConceptScore W596445770C86803240 @default.
• W596445770 hasConceptScore W596445770C9086966 @default.
• W596445770 hasLocation W5964457701 @default.
• W596445770 hasOpenAccess W596445770 @default.
• W596445770 hasPrimaryLocation W5964457701 @default.
• W596445770 hasRelatedWork W1516684622 @default.
• W596445770 hasRelatedWork W1545251509 @default.
• W596445770 hasRelatedWork W1567848155 @default.
• W596445770 hasRelatedWork W1969535489 @default.
• W596445770 hasRelatedWork W1969959842 @default.
• W596445770 hasRelatedWork W1972591350 @default.
• W596445770 hasRelatedWork W1998949205 @default.
• W596445770 hasRelatedWork W2010900115 @default.
• W596445770 hasRelatedWork W2043048893 @default.
• W596445770 hasRelatedWork W2089873957 @default.
• W596445770 hasRelatedWork W2107386887 @default.
• W596445770 hasRelatedWork W2107557025 @default.
• W596445770 hasRelatedWork W2108088710 @default.
• W596445770 hasRelatedWork W2115063969 @default.
• W596445770 hasRelatedWork W2137221978 @default.
• W596445770 hasRelatedWork W2168962590 @default.
• W596445770 hasRelatedWork W2752643056 @default.
• W596445770 hasRelatedWork W2917527275 @default.
• W596445770 hasRelatedWork W2925049304 @default.
• W596445770 hasRelatedWork W3020176292 @default.
• W596445770 isParatext "false" @default.
• W596445770 isRetracted "false" @default.
• W596445770 magId "596445770" @default.
• W596445770 workType "article" @default.